Trial Profile
Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Orlistat
- Indications Obesity
- Focus Biomarker; Therapeutic Use
- Sponsors Novo Nordisk
- 19 May 2016 Results of a post hoc dose-proportionality assessment (n=331) published in the Clinical Pharmacokinetics.
- 11 Jul 2010 Results of the 84-week extension trial were presented at the 11th International Congress on Obesity.
- 24 Oct 2009 Results of planned 52-week interim analysis presented at the 2009 Annual Meeting of the North American Association for the Study of Obesity.